Cachexia Research Laboratory, Exercise Science Research Center, Department of Health, Human Performance and Recreation, University of Arkansas, Fayetteville, Arkansas.
Exercise Muscle Biology Laboratory, Exercise Science Research Center, Department of Health, Human Performance and Recreation, University of Arkansas, Fayetteville, Arkansas.
J Appl Physiol (1985). 2022 Jan 1;132(1):58-72. doi: 10.1152/japplphysiol.00660.2021. Epub 2021 Nov 11.
Cancer cachexia (CC) results in impaired muscle function and quality of life and is the primary cause of death for ∼20%-30% of patients with cancer. We demonstrated mitochondrial degeneration as a precursor to CC in male mice; however, whether such alterations occur in females is currently unknown. The purpose of this study was to elucidate muscle alterations in CC development in female tumor-bearing mice. Sixty female C57BL/6J mice were injected with PBS or Lewis lung carcinoma at 8 wk of age, and tumors developed for 1, 2, 3, or 4 wk to assess the time course of cachectic development. In vivo muscle contractile function, protein fractional synthetic rate (FSR), protein turnover, and mitochondrial health were assessed. Three- and four-week tumor-bearing mice displayed a dichotomy in tumor growth and were reassigned to high tumor (HT) and low tumor (LT) groups. HT mice exhibited lower soleus, tibialis anterior, and fat weights than PBS mice. HT mice showed lower peak isometric torque and slower one-half relaxation time than PBS mice. HT mice had lower FSR than PBS mice, whereas E3 ubiquitin ligases were greater in HT than in other groups. (mitophagy) and pMitoTimer red puncta (mitochondrial degeneration) were greater in HT mice, whereas and (mitochondrial biogenesis) were lower in HT mice than in PBS mice. We demonstrate alterations in female tumor-bearing mice where HT exhibited greater protein degradation, impaired muscle contractility, and mitochondrial degeneration compared with other groups. Our data provide novel evidence for a distinct cachectic development in tumor-bearing female mice compared with previous male studies. Our study demonstrates divergent tumor development and tissue wasting within 3- and 4-wk mice, where approximately half the mice developed large tumors and subsequent cachexia. Unlike previous male studies, where metabolic perturbations precede the onset of cachexia, females appear to exhibit protections from the metabolic perturbations and cachexia development. Our data provide novel evidence for divergent cachectic development in tumor-bearing female mice compared with previous male CC studies, suggesting different mechanisms of CC between sexes.
癌症恶病质(CC)导致肌肉功能和生活质量受损,是约 20%-30%癌症患者死亡的主要原因。我们在雄性小鼠中证明了线粒体退化是 CC 的前兆;然而,这种改变是否发生在雌性中目前尚不清楚。本研究旨在阐明荷瘤雌性小鼠 CC 发展中的肌肉改变。60 只 8 周龄 C57BL/6J 雌性小鼠注射 PBS 或 Lewis 肺癌细胞,肿瘤生长 1、2、3 或 4 周,以评估恶病质发展的时间进程。评估了体内肌肉收缩功能、蛋白质分数合成率(FSR)、蛋白质周转率和线粒体健康。荷瘤 3 周和 4 周的小鼠显示出肿瘤生长的二分法,并被重新分配到高肿瘤(HT)和低肿瘤(LT)组。HT 小鼠的比目鱼肌、胫骨前肌和脂肪重量低于 PBS 小鼠。HT 小鼠的峰值等长扭矩和半松弛时间比 PBS 小鼠慢。HT 小鼠的 FSR 低于 PBS 小鼠,而 HT 小鼠的 E3 泛素连接酶高于其他组。(线粒体自噬)和 pMitoTimer 红色斑点(线粒体退化)在 HT 小鼠中更大,而(线粒体生物发生)在 HT 小鼠中低于 PBS 小鼠。我们在荷瘤雌性小鼠中观察到改变,其中 HT 与其他组相比,表现出更大的蛋白质降解、肌肉收缩力受损和线粒体退化。我们的数据为荷瘤雌性小鼠与之前的雄性研究相比,恶病质发展存在明显差异提供了新的证据。我们的研究表明,在 3 周和 4 周的小鼠中,肿瘤的发展和组织消耗存在差异,大约一半的小鼠发展出大肿瘤和随后的恶病质。与之前的雄性研究不同,代谢紊乱先于恶病质的发生,而雌性似乎免受代谢紊乱和恶病质发展的影响。我们的数据为荷瘤雌性小鼠与之前的雄性 CC 研究相比,恶病质发展存在明显差异提供了新的证据,表明性别之间存在不同的 CC 机制。